Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Exploring the relationship between self-reported urinary tract infections to quality of life and associated conditions: insights from the spinal cord injury Community Survey.

Locke JA, Welk B, Macnab A, Rivers CS, Kurban D, Nigro M, Stothers L.

Spinal Cord. 2019 Dec;57(12):1040-1047. doi: 10.1038/s41393-019-0323-z. Epub 2019 Jul 9.

PMID:
31289367
2.

A comprehensive review of adult enuresis.

Akhavizadegan H, Locke JA, Stothers L, Kavanagh A.

Can Urol Assoc J. 2018 Sep 27:282-287. doi: 10.5489/cuaj.5485. [Epub ahead of print] Review.

3.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

4.

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.

5.

Treatment of varicocele in children and adolescents: A systematic review and meta-analysis of randomized controlled trials.

Locke JA, Noparast M, Afshar K.

J Pediatr Urol. 2017 Oct;13(5):437-445. doi: 10.1016/j.jpurol.2017.07.008. Epub 2017 Aug 9. Review.

PMID:
28851509
6.

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.

Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG.

Front Oncol. 2016 Feb 16;6:24. doi: 10.3389/fonc.2016.00024. eCollection 2016. Review.

7.

Next generation biomarkers in prostate cancer.

Locke JA, Black PC.

Front Biosci (Landmark Ed). 2016 Jan 1;21:328-42. Review.

PMID:
26709776
8.

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.

Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ.

Clin Genitourin Cancer. 2016 Aug;14(4):331-40. doi: 10.1016/j.clgc.2015.10.005. Epub 2015 Oct 24.

9.

Synergistic action of image-guided radiotherapy and androgen deprivation therapy.

Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG.

Nat Rev Urol. 2015 Apr;12(4):193-204. doi: 10.1038/nrurol.2015.50. Epub 2015 Mar 24. Review.

PMID:
25800395
10.

Victims of road rage: a qualitative study of the experiences of motorists and vulnerable road users.

Cavacuiti C, Ala-Leppilampi KJ, Mann RE, Govoni R, Stoduto G, Smart R, Locke JA.

Violence Vict. 2013;28(6):1068-84.

PMID:
24547681
11.

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.

Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG.

Cancer. 2012 Aug 15;118(16):4053-62. doi: 10.1002/cncr.26729. Epub 2012 Jan 26. Erratum in: Cancer. 2014 Aug 1;120(15):2380. Jurisca, Igor [corrected to Jurisica, Igor].

12.

Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.

Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG.

Prostate. 2012 Sep 1;72(12):1295-305. doi: 10.1002/pros.22478. Epub 2011 Dec 27.

PMID:
22213075
13.

NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.

Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, Malloff CA, Lam WL, Squire JA, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, van der Kwast T, Bristow RG.

Clin Cancer Res. 2012 Jan 1;18(1):308-16. doi: 10.1158/1078-0432.CCR-11-2147. Epub 2011 Nov 2.

14.

Insulin increases de novo steroidogenesis in prostate cancer cells.

Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC.

Cancer Res. 2011 Sep 1;71(17):5754-64. doi: 10.1158/0008-5472.CAN-10-2470. Epub 2011 Jul 11.

15.

Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy.

Locke JA, Bruchovsky N.

Can J Urol. 2010 Jun;17(3):5162-9.

PMID:
20566007
16.

Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.

Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM.

Prostate. 2010 Mar 1;70(4):390-400. doi: 10.1002/pros.21072.

PMID:
19866465
17.

Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.

Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC.

Prostate. 2010 Feb 15;70(3):239-51. doi: 10.1002/pros.21057.

PMID:
19790237
18.

Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.

Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns ES.

J Steroid Biochem Mol Biol. 2009 Jul;115(3-5):126-36. doi: 10.1016/j.jsbmb.2009.03.011. Epub 2009 Apr 5.

PMID:
19442514
19.

A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer.

Locke JA, Fazli L, Adomat H, Smyl J, Weins K, Lubik AA, Hales DB, Nelson CC, Gleave ME, Tomlinson Guns ES.

Prostate. 2009 Jun 15;69(9):928-37. doi: 10.1002/pros.20940.

PMID:
19267349
20.

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.

22.

Establishing an education program for non-English-speaking families.

Locke JA.

J Pediatr Nurs. 1992 Jun;7(3):227-8. No abstract available.

PMID:
1625181
23.

Workplace compliance with a no-smoking law: a randomized community intervention trial.

Rigotti NA, Bourne D, Rosen A, Locke JA, Schelling TC.

Am J Public Health. 1992 Feb;82(2):229-35. Erratum in: Am J Public Health 1992 May;82(5):684.

24.

Sampling events in space and time: a case study of burn injuries.

Hanley JA, Burke JF, Locke JA, Boyle CM.

Burns. 1991 Apr;17(2):104-9.

PMID:
2054067
25.
26.
27.

Paediatric burn injuries in New England, USA.

Rossignol AM, Locke JA, Burke JF.

Burns. 1990 Feb;16(1):41-8.

PMID:
2322394
28.

Employment status and the frequency and causes of burn injuries in New England.

Rossignol AM, Locke JA, Burke JF.

J Occup Med. 1989 Sep;31(9):751-7.

PMID:
2795252
29.

Epidemiology of work-related burn injuries in Massachusetts requiring hospitalization.

Rossignol AM, Locke JA, Boyle CM, Burke JF.

J Trauma. 1986 Dec;26(12):1097-101.

PMID:
3795306
30.

Hospitalized burn injuries in Massachusetts: an assessment of incidence and product involvement.

Rossignol AM, Boyle CM, Locke JA, Burke JF.

Am J Public Health. 1986 Nov;76(11):1341-3.

31.

Socioeconomic factors and burn rates in persons hospitalized for burns in Massachusetts.

Locke JA, Rossignol AM, Boyle CM, Burke JF.

Public Health Rep. 1986 Jul-Aug;101(4):389-95.

32.

Consumer products and hospitalized burn injuries among elderly Massachusetts residents.

Rossignol AM, Locke JA, Boyle CM, Burke JF.

J Am Geriatr Soc. 1985 Nov;33(11):768-72.

PMID:
4056272
33.

An assessment of the completeness of the Massachusetts Burn Registry.

Rossignol AM, Locke JA.

Public Health Rep. 1983 Sep-Oct;98(5):492-6.

34.

THE USE OF TIME AND COST DATA IN ENVIRONMENTAL HEALTH PROGRAM PLANNING.

LOCKE JA.

Am J Public Health Nations Health. 1964 Mar;54:501-5. No abstract available.

Supplemental Content

Loading ...
Support Center